ASCO 2025 | New insight into genitourinary cancer irAEs optimize patient outcomes
Chiara Mercinelli, MD, IRCCS San Raffaele Hospital, Milan, Italy comments on immune-related adverse events (irAEs) in genitourinary cancers. Toxicity tends to be more frequent in adjuvant and perioperative settings, demanding earlier toxicity management to prevent discontinuing treatment. Improved understanding of these toxicities has made this increasingly possible, underscoring the importance of multidisciplinary coordination to optimize patient outcome. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We recently conducted a review on the immunotherapy toxicity across all the GU fields, in particular in bladder, prostate and kidney cancer. What is interesting is that sometimes we notice more toxicities in the adjuvant or perioperative settings but if we really know all those kinds of toxicities, if we are able to recognize them, we can stop them early and manage the toxicity without stopping the treatment...
We recently conducted a review on the immunotherapy toxicity across all the GU fields, in particular in bladder, prostate and kidney cancer. What is interesting is that sometimes we notice more toxicities in the adjuvant or perioperative settings but if we really know all those kinds of toxicities, if we are able to recognize them, we can stop them early and manage the toxicity without stopping the treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Travel, Accommodations, Expenses – Johnson & Johnson/Janssen
